Zai Lab (ZLAB) Cash from Investing Activities (2018 - 2026)
Zai Lab (ZLAB) posted quarterly Cash from Investing Activities of -$22.3 million for Q1 2026, down 106.83% year-on-year from $326.1 million in Q1 2025, and down 97.31% on a QoQ basis from -$11.3 million in Q4 2025.
Zai Lab (ZLAB) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Cash from Investing Activities for 9 consecutive years, with -$22.3 million the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities fell 106.83% year-over-year to -$22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.6 million (up 22.53% YoY) and the FY2025 annual result came in at $307.9 million, up 182.06% from the prior year.
- Cash from Investing Activities slipped to -$22.3 million in Q1 2026 per ZLAB's latest filing, from -$11.3 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ZLAB reached as high as $568.3 million in Q3 2022 and fell as low as -$347.8 million in Q4 2024.
- A 5-year average of $18.8 million and a median of -$4.4 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 2622.65% — and 2025, when it soared 9806.83%.
- Year by year, Cash from Investing Activities stood at -$4.4 million in 2022, then jumped by 430.6% to $14.5 million in 2023, then sank by 2505.44% to -$347.8 million in 2024, then jumped by 96.75% to -$11.3 million in 2025, then slumped by 97.31% to -$22.3 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$22.3 million, -$11.3 million, and -$4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Zai Lab | 20.66 Bn | 19.91 Bn | 61.30 Mn | -22.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.29 Mn |
| Mar 31, 2026 | -22.29 Mn |
| Dec 31, 2025 | -11.30 Mn |
| Dec 31, 2025 | -11.30 Mn |
| Sep 30, 2025 | -4.05 Mn |
| Sep 30, 2025 | -4.05 Mn |
| Jun 30, 2025 | -2.92 Mn |
| Jun 30, 2025 | -2.92 Mn |
| Mar 31, 2025 | 326.13 Mn |
| Mar 31, 2025 | 326.13 Mn |
| Dec 31, 2024 | -347.75 Mn |
| Dec 31, 2024 | -347.75 Mn |
| Sep 30, 2024 | -29.89 Mn |
| Sep 30, 2024 | -29.89 Mn |
| Jun 30, 2024 | -846,000.00 |
| Jun 30, 2024 | -846,000.00 |
| Mar 31, 2024 | 3.29 Mn |
| Mar 31, 2024 | 3.29 Mn |
| Dec 31, 2023 | 14.46 Mn |
| Dec 31, 2023 | 14.46 Mn |